Keith Thomas Flaherty, M.D.
This page shows the publications co-authored by Keith Flaherty and James Mier.
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discov. 2018 02; 8(2):184-195.
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. Oncologist. 2015 Jun; 20(6):617-8.
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. . 2014 Dec; 13(12):3210-8.
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286.
A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). J Clin Oncol. 2009 May 20; 27(15_suppl):5101.
Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2291s-2296s.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.